Company Mesoblast Limited

Equities

MSB

AU000000MSB8

Biotechnology & Medical Research

Delayed Australian S.E. Other stock markets 02:55:36 09/02/2026 GMT			5-day change	1st Jan Change
2.360 ^AUD	+5.83%		-4.45%	-13.24%

02-06	ASX Biggest Losers	MT
01-29	Mesoblast to Start Site Enrollment in Pivotal Trial for Cell Therapy Label Extension; Shares Fall 4%	MT

Business description: Mesoblast Limited

Mesoblast Limited is an Australia-based company, which is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. It has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. It is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for advanced chronic heart failure (REVASCOR) and chronic low back pain (MPC-06-ID). Two products have been commercialized in Japan and Europe by the Company's licensees. It has established commercial partnerships in Europe and China for certain Phase III assets.

Number of employees: 81

Sales by Activity: Mesoblast Limited

Fiscal Period: June	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)
Development of Cell Technology Platform for Commercialization	7.46M	10.21M	7.5M	5.9M	17.2M

See all business segments

Executive Committee: Mesoblast Limited

Manager	Title	Age	Since
Silviu Itescu CEO	Chief Executive Officer	69	22/03/2011
James O'Brien DFI	Director of Finance/CFO	59	16/11/2025
Eric Rose CTO	Chief Tech/Sci/R&D Officer	75	31/01/2022
Paul Hughes IRC	Investor Relations Contact	-	31/01/2019
Niva Sivakumar SEC	Corporate Secretary	-	28/10/2019

See MESOBLAST LIMITED governance

Composition of the Board of Directors: Mesoblast Limited

Director	Title	Age	Since
Silviu Itescu BRD	Director/Board Member	69	31/12/2006
Eric Rose BRD	Director/Board Member	75	14/04/2013
William Burns BRD	Director/Board Member	78	05/03/2014
Philip Facchina CHM	Chairman	64	01/01/2026
Philip Krause BRD	Director/Board Member	-	23/03/2022
Jane Bell CHM	Chairman	-	28/04/2024
Gregory George BRD	Director/Board Member	-	23/02/2025
Lynette Cobley BRD	Director/Board Member	-	28/04/2025

Composition of the Board of Directors

Shareholders: Mesoblast Limited

Name	Equities	%	Valuation
Gregory George 20.87 %	267,815,622	20.87 %	486 M $
Silviu Itescu 6.154 %	78,958,928	6.154 %	143 M $
William Gueck 5.002 %	64,171,900	5.002 %	116 M $
Thorney Investment Group Australia Pty Ltd. 1.1 %	14,116,398	1.1 %	26 M $
Josaka Investments Pty Ltd. 0.6876 %	8,821,137	0.6876 %	16 M $

Name	Equities	%	Valuation
Legal & General Investment Management Ltd. 0.5077 %	651,416	0.5077 %	12 M $
Aperio Group LLC 0.4002 %	513,399	0.4002 %	9 M $
Morgan Stanley Capital Services LLC 0.3631 %	465,801	0.3631 %	8 M $
Goldman Sachs & Co. LLC 0.3175 %	407,280	0.3175 %	7 M $
Susquehanna Securities LLC 0.2116 %	271,488	0.2116 %	5 M $

List of MESOBLAST LIMITED shareholders

Company details: Mesoblast Limited

Mesoblast Ltd.

55 Collins Street

3000, Melbourne

+61 3 9639 6036

http://www.mesoblast.com

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
MESOBLAST LIMITED	+5.83%	-4.45%	-21.85%	+100.00%	2.02B
LONZA GROUP AG	-0.19%	-1.49%	-14.34%	-7.25%	46.82B
BEONE MEDICINES AG	+1.99%	+3.98%	+58.35%	+41.59%	39.16B
CELLTRION, INC.	+1.15%	+4.76%	+27.39%	+43.86%	32.9B
IQVIA HOLDINGS INC.	+3.61%	-18.54%	-9.92%	-20.39%	31.8B
REVOLUTION MEDICINES, INC.	+1.39%	+0.56%	+131.07%	+289.65%	18.85B
MEDPACE HOLDINGS, INC.	+0.14%	-6.94%	+53.08%	+132.04%	15.27B
Average	+1.99%	-3.70%	+31.97%	+82.79%	26.69B
Weighted average by Cap.	+1.40%	-1.86%	+29.10%	+52.25%